In patients with RA, TNF inhibitor use during the 3 years after being diagnosed with early-stage lung, colorectal, or prostate cancer was not linked to decreased survival.

Furthermore, clinical and experimental studies show that the efficacy of the three currently licensed anti-TNF agents (infliximab, etanercept and adalimumab) may vary and depend on the type of ...

Three other TNF-blocking agents (etanercept, adalimumab and certolizumab pegol) are now approved for a variety of indications. It is fair to say that anti-TNF therapy has revolutionized the ...

TNF inhibitor use demonstrates no negative impact on survival among patients recently diagnosed with colorectal, lung or ...

Tumor necrosis factor (TNF)-alpha, a proinflammatory cytokine, has been implicated in the pathogenesis of AD. Objective: To investigate the use of a biologic TNF-alpha inhibitor, etanercept was ...